Dutasteride

Dutasteride

Dutasteride is the strongest available drug for shutting down the conversion of testosterone to DHT, the hormone that drives male and female pattern hair loss, prostate enlargement, and frontal fibrosing alopecia. It was originally developed and approved for benign prostatic hyperplasia (BPH), where it shrinks an enlarged prostate over time. Most people now take it off-label at the same 0.5 mg daily dose for hair loss, where it consistently outperforms finasteride in head-to-head trials.
Finasteride blocks one of the two 5-alpha-reductase enzymes and drops blood DHT by around 70%. Dutasteride blocks both and drops it by around 95%. In practice that translates to more hair regrown, more thinning halted, and a much longer drug half-life (around 5 weeks) so missed doses don't matter much. The trade is that the same DHT suppression that protects your hair also affects libido, mood, and ejaculation volume in a meaningful minority of users, and the long half-life means side effects, when they happen, take longer to clear. This is a serious drug, not a supplement, and the decision to start it should be made with a clear-eyed view of both sides.

Deep-dive

Androgenetic alopecia, BPH, and frontal fibrosing alopecia are all driven, at least partly, by DHT, a more potent androgen made from testosterone by an enzyme called 5-alpha-reductase. There are two isoforms of this enzyme. Type 2 dominates in the prostate, hair follicles, and male genital skin. Type 1 dominates in skin, sebaceous glands, liver, and the central nervous system, with significant expression in the scalp as well. Finasteride blocks only type 2. Dutasteride blocks both, and irreversibly, which is what produces the deeper DHT suppression.
Pharmacokinetics matter for how this drug is used. Dutasteride is highly lipophilic, distributes widely, and binds tightly to plasma proteins. The Gisleskog pharmacokinetic modelling paper characterised the elimination as parallel linear and nonlinear, with a terminal half-life of up to 5 weeks at therapeutic concentrations. The practical consequence is that steady-state is reached over months, not days, and missing a dose has almost no effect on circulating drug level. UCLA researchers noted that a patient who forgets a dutasteride dose won't experience the DHT rebound seen with missed finasteride doses. This is why many users move to every-other-day or 2-3 times weekly dosing once stable, the receptor occupancy and DHT suppression hold up.
The hair loss evidence. The foundational head-to-head trial is Olsen 2006, which randomised 416 men with male pattern hair loss to dutasteride 0.05, 0.1, 0.5, or 2.5 mg, finasteride 5 mg, or placebo for 24 weeks. Hair count and hair width increased dose-dependently with dutasteride, and dutasteride 2.5 mg was superior to finasteride at both 12 and 24 weeks. The larger 2014 dose-finding trial in 917 men replicated this with the now-standard 0.5 mg dose, showing it significantly outperformed finasteride 1 mg on hair count, hair width, and panel photographic assessment by week 24. The 2019 systematic review and meta-analysis of 576 patients across three RCTs put a number on it: dutasteride users gained a mean of 28.57 more hairs per assessment area than finasteride users over 24 weeks. A separate network meta-analysis of 30 RCTs reached the same conclusion across the broader hair loss literature.
Long-term real-world data. The Korean multicentre chart review tracked dutasteride and finasteride users over multiple years in routine clinical practice and confirmed the pattern: dutasteride users had better hair growth outcomes with a tolerability profile broadly similar to finasteride. Dutasteride is officially approved for androgenetic alopecia in South Korea, Japan, and Taiwan at 0.5 mg daily; the FDA approval in the US is only for BPH, which is why most US prescribing for hair loss is off-label.
Topical and mesotherapy approaches. The downside of oral dutasteride is the long-lasting systemic DHT suppression. Topical formulations and intradermal mesotherapy try to keep the drug at the scalp and minimise the rest. A 2024 Phase II topical solution trial compared 0.01%, 0.02%, and 0.05% topical dutasteride against finasteride 1 mg and placebo over 24 weeks. The 0.05% solution beat oral finasteride on hair count, with systemic dutasteride exposure mostly below the limit of quantification and no significant change in serum testosterone or DHT in the topical groups. The Vañó-Galván 2022 multicentre retrospective study of 541 patients receiving dutasteride mesotherapy (intradermal injection every 3 months) found the treatment effective in both men and women with mild, self-limited side effects, supporting the case that local delivery can decouple the scalp effect from systemic suppression. The evidence is real but still thinner than for oral dosing, and product quality varies between compounding pharmacies.
BPH and prostate. Dutasteride 0.5 mg reduces prostate volume by around 25% over 2 years and lowers serum PSA by roughly 50% within 6 months. The REDUCE trial, a 4-year placebo-controlled study in over 8,000 men, showed dutasteride significantly reduced the risk of acute urinary retention and BPH-related surgery across all prostate volume quintiles. The same trial found a 23% reduction in biopsy-detected prostate cancer overall, but a small absolute increase in high-grade Gleason 8-10 tumours in the dutasteride arm. The follow-up analyses argue this likely reflects detection bias (smaller prostates are easier to biopsy accurately) rather than the drug causing more aggressive cancers, but the FDA still requires a warning. In practical terms: if you're using dutasteride and getting PSA tested, the result has to be doubled to interpret it properly, and any rise from your on-drug nadir is a stronger signal than the absolute number.
Women. Dutasteride is FDA pregnancy category X. Women of reproductive age generally cannot use it because of the risk of feminisation of a male fetus. In postmenopausal women and women on reliable contraception, however, oral dutasteride is one of the more effective treatments for female pattern hair loss and is considered first-line for frontal fibrosing alopecia. The 2024 systematic review and meta-analysis of dutasteride for FFA pooled data across multiple studies and found stabilisation of hair loss in around 70% of treated women. The Pindado-Ortega 2021 series of 224 patients (222 women) showed stabilisation rates of 62-64% in the frontal and temporal regions on dutasteride versus 30-41% with no systemic treatment over 12 months. The 2025 JAAD scoping review summarised the female pattern hair loss data, noting dutasteride 0.15 mg/day over 3 years improves FPHL in up to 80% of patients in observational series. Doses for women tend to run lower than for men (0.15-0.5 mg, often started at twice weekly), reflecting that lower androgen drive in women means less drug is needed and the side effect ceiling sits lower. Pre-menopausal women on dutasteride must be on reliable contraception throughout treatment and should not handle broken capsules.
Post-finasteride syndrome and persistent side effects. This is the hardest topic in the 5-ARI literature to discuss honestly. A meaningful minority of users on either finasteride or dutasteride develop sexual side effects (lowered libido, erectile dysfunction, reduced ejaculate volume) and in some cases mood changes. In most users these are reversible on discontinuation. In a smaller subset, symptoms persist beyond drug clearance, sometimes for years. This is called post-finasteride syndrome (PFS), and the same syndrome can follow dutasteride use. A 2020 review summarises the mechanistic hypotheses: 5-AR is required for the synthesis of neuroactive steroids (allopregnanolone, 3α-androstanediol) in the brain that regulate GABA-A receptors, and chronic 5-AR inhibition appears to durably alter neurosteroid profiles and possibly androgen receptor expression in a subset of users. The clinical reality is that PFS is real, the underlying biology is partially understood, and the prevalence is genuinely unclear because most trials never followed users long enough after stopping to capture it. The honest read is that 5-ARI side effects are usually reversible, occasionally persistent, and the risk of the persistent variant is small but not zero. SSRI use, younger age, and longer duration of treatment may be risk factors. Anyone considering dutasteride should know this before starting.
Stacking. The standard stack for hair loss is dutasteride + topical or oral Minoxidil. The two compounds hit different mechanisms (DHT suppression vs follicle stimulation via the K-ATP channel pathway) and the combination consistently outperforms either alone. Adding a topical anti-androgen like RU58841 on top of oral dutasteride is overkill for most users and reintroduces local anti-androgen exposure that the systemic suppression has already largely handled. Where stacking RU does make sense is for partial responders who want more scalp coverage without escalating the oral dose. Red light therapy is a reasonable adjunct with no overlap in mechanism or side effect profile.

Dosage:

  • Standard dose for hair loss: 0.5 mg daily, oral, the same dose used in BPH. This is the dose with the most evidence behind it and the one approved in Korea, Japan, and Taiwan for AGA. Once steady-state is reached (around 3-6 months), many users move to every other day or 2-3 times weekly with similar DHT suppression, taking advantage of the 5-week half-life. There's no clean RCT comparing daily to intermittent dosing in men long-term, but the pilot data on twice and thrice weekly dosing showed comparable hair count gains to daily finasteride
  • Standard dose for BPH: 0.5 mg daily. Same capsule, same molecule, just framed around a different indication. Effect on prostate volume builds over months and is maintained as long as treatment continues
  • Women (post-menopausal or on reliable contraception): 0.15-0.5 mg daily for female pattern hair loss, often started at the lower end or at twice-weekly dosing. For frontal fibrosing alopecia, 0.5 mg daily is the typical starting dose, sometimes reduced to once weekly for maintenance. Pre-menopausal women without reliable contraception should not use oral dutasteride at all
  • Topical: 0.01-0.05% solution applied once daily to the scalp, typically in an ethanol/PG vehicle. The 0.05% concentration showed the strongest hair count effect in the Phase II trial with very low systemic exposure. Quality of compounded topical varies, prefer pharmacies with HPLC purity testing
  • Mesotherapy: 0.01% dutasteride injected intradermally into the scalp at monthly to quarterly intervals by a trained clinician. This is in-clinic only, not for self-administration
  • Timing: Take orally with or without food, the absorption is unaffected by meals. Timing of day doesn't matter given the long half-life. Consistency matters more than timing
  • Stopping: DHT returns to baseline over roughly 4-6 months as the drug clears. Hair benefits typically reverse over 6-12 months. This is not a drug you stop and start casually, the long washout means side effects, if any, also take a while to fully resolve

Here's what you can expect:

The first 3-6 months you'll see very little visible change, and you may even shed more in the first few weeks as follicles cycle from telogen back into anagen. By month 6, hair on top of the head looks thicker in consistent-lighting photos, and shedding rates drop. By month 12, regrowth in previously thinned areas is usually visible. Peak hair count gains typically arrive at 12-24 months and are maintained with continued use. If you've crossed into significant Norwood 5 or 6 territory, expect maintenance and partial thickening rather than full reversal. The follicle has to still be alive to come back.
For BPH, urinary symptoms (frequency, urgency, weak stream) usually start improving by month 3 and reach plateau by month 12. Prostate volume reduction is gradual and reaches around 25% by 2 years.
If you experience sexual side effects, they usually appear within the first 1-3 months. For most users they're mild and fade with continued use as the body adapts. For a minority they persist and require dose reduction or discontinuation. Watch the first 90 days closely.

Side effects & risks:

  • Sexual side effects (reduced libido, erectile dysfunction, reduced ejaculate volume) are the most common and most clinically relevant issue. Reported rates in the 0.5 mg dutasteride trials sit in the 4-7% range, broadly similar to finasteride 1 mg per pooled meta-analyses, despite the deeper DHT suppression. Most reverse on discontinuation within weeks to months as the drug clears
  • Post-finasteride / post-5ARI syndrome. A subset of users develop persistent sexual, mood, or cognitive symptoms that continue after stopping the drug, sometimes for years. The biology involves neuroactive steroid synthesis in the brain, which depends on 5-AR. Prevalence is unclear but not zero, and risk appears higher with longer duration of use, younger age at start, and concurrent SSRI use. This is the strongest reason to think carefully before starting and to keep the duration of any trial period bounded and observed
  • Mood changes (low mood, anxiety, brain fog) are reported by some users during treatment. Usually reversible. If you have a history of clinical depression, this is worth flagging before starting
  • Gynecomastia and breast tenderness occur in roughly 1-2% of users due to the shifted testosterone-to-oestradiol ratio (more substrate diverted away from DHT means more aromatised to oestradiol). Usually mild, reversible on discontinuation
  • PSA halving is expected and not a side effect per se, but it confounds prostate cancer screening. Any PSA result on dutasteride must be multiplied by 2 to compare against normal reference ranges, and any rise from your on-drug nadir is a stronger flag than the absolute value
  • Prostate cancer (high-grade signal). The REDUCE trial showed a small absolute increase in high-grade Gleason 8-10 tumour detection on dutasteride, though the consensus view is that this reflects detection bias from smaller, more accurately biopsied prostates. The FDA black box warning remains. For young men using dutasteride for hair loss, this is a low-priority concern; for older men using it for BPH, it's relevant context for monitoring
  • Pregnancy category X. Dutasteride is absorbed through skin from broken capsules and can interfere with development of male fetal genitalia. Pregnant women must not handle the capsules. Men taking dutasteride should not donate blood during treatment or for 6 months after stopping (the standard is that a unit of blood from a dutasteride user could expose a pregnant recipient)
  • Decreased fertility. Reduced ejaculate volume and sperm parameters are documented. If you're actively trying to conceive, hold dutasteride until after conception, or use a topical formulation instead
  • Drug interactions are mainly via CYP3A4. Strong inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase dutasteride exposure. Most users don't need a dose adjustment given the wide therapeutic window, but it's worth knowing if you start a new medication. Saw palmetto has weak 5-AR activity and stacking it on top is redundant
  • Liver. Metabolised hepatically via CYP3A4. Use with caution in significant liver impairment, dose adjustment may be needed
  • Cardiovascular. No clinically significant effect on lipids or blood pressure in the BPH trials
  • The long half-life is its own risk profile. Side effects that show up take longer to clear than with finasteride (5+ weeks rather than days). This cuts both ways: missed doses don't matter, but a regretted decision takes months to fully reverse
🩸

Blood markers

Total testosterone, free testosterone, DHT, SHBG, oestradiol, LH, FSH, baseline before starting and at 3-6 months on treatment. Expect DHT to drop by around 90-95% and testosterone to rise modestly (often 10-20%) as substrate accumulates. Oestradiol typically rises slightly. SHBG can shift. The goal is to confirm the drug is working as expected and to establish a reference point for any later symptoms
PSA, baseline before starting if over 40, then annually. Expect a roughly 50% drop within 6 months. To interpret any future PSA, double the on-drug value to compare against standard reference ranges. Any rise from your on-drug nadir is more important than the absolute number
Liver enzymes (ALT, AST), baseline and at 6-12 months. Dutasteride is hepatically metabolised and while clinically significant hepatotoxicity is rare, a baseline gives you a reference
Lipid panel, baseline. No expected change but useful in context of overall cardiometabolic monitoring
Mood and sexual function are not blood markers but should be assessed at baseline using a simple subjective scale (libido 1-10, erection quality 1-10, mood 1-10) and rechecked at month 1 and 3. A documented baseline matters if symptoms later raise the question of attribution
For women specifically: cycle-day-3 oestradiol, progesterone (luteal phase if pre-menopausal), free testosterone, DHEA-S, SHBG, baseline before starting. Recheck at 6 months. Anti-androgen exposure can shift these and you want a reference point. Pre-menopausal women must also have a documented pregnancy test before starting and reliable contraception confirmed
For a male using oral 0.5 mg dutasteride for hair loss, the practical minimum is a baseline hormone panel (total T, free T, DHT, oestradiol, SHBG) plus PSA if over 40, then a 6-month recheck. Annual after that if stable. Anyone with a pre-existing history of depression, sexual dysfunction, or hormonal issues needs more frequent subjective monitoring rather than more bloodwork
Approved for benign prostatic hyperplasia in most countries; approved for androgenetic alopecia in South Korea, Japan, and Taiwan. Prescription-only.